Tag: Ecosystem-Based Models

The quiet truth about rare disease medicines is that a brilliant molecule or a one-time gene therapy is only the opening act. Getting the drug from a lab bench miracle into durable, equitable patient benefit now depends on an orchestra of services, diagnostics, payers, and... Continue reading